Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Salarius Pharmaceuticals ( (SLRX) ) has issued an announcement.
Salarius Pharmaceuticals has entered into a merger agreement with Decoy Therapeutics, resulting in a stock-for-stock transaction where Decoy stockholders will own approximately 85.9% of Salarius. The merger aims to combine Salarius and Decoy’s operations, with Decoy becoming a wholly-owned subsidiary. This merger is expected to significantly impact Salarius’ operations and industry positioning, as Decoy’s significant operations will contribute to the future of the combined company. The merger was approved by both companies’ board of directors and involves a special stockholder meeting to address various proposals related to the merger.
More about Salarius Pharmaceuticals
YTD Price Performance: -10.06%
Average Trading Volume: 352,459
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.26M
Find detailed analytics on SLRX stock on TipRanks’ Stock Analysis page.